RxDoctor Payments DataLook up a doctor →

Abdul Jabbar, MD

Gastroenterology · New Albany, INNPI 1437141835

Payments from drug & device makers

$32,831in general payments, 2019–2025

Across 602 payments — averaging $54.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$17K
  • AstraZeneca$9K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$981
  • Takeda Pharmaceuticals U.S.A., Inc.$818
  • Gilead$425
  • plus $3K from 38 others
$1,198in research payments, 2019–2025

Across 1 payment — averaging $1198.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K

What the payments were for

  • Food & beverage$9,345100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,831 in reported general payments places this provider in the 85th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$518,849
Medicare patients
967
Services billed
18,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab21$533,787
Humira(Cf) PenAdalimumab18$158,845
LinzessLinaclotide127$129,972
CreonLipase/Protease/Amylase44$112,339
ZenpepLipase/Protease/Amylase16$34,374
MotegrityPrucalopride Succinate14$20,390
Ursodiol78$12,969
Dexlansoprazole DrDexlansoprazole32$11,290
Mesalamine21$9,521
Budesonide DrBudesonide28$6,935
Sucralfate147$5,316
Colestipol Hcl87$4,976
Budesonide EcBudesonide15$4,822
Omeprazole571$4,046
Balsalazide Disodium15$3,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$981$533,78721 claims
AbbVieLinzess, Creon$17,353$242,310171 claims
Aimmune Therapeutics, Inc.Zenpep$53$34,37416 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$818$20,39014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in New Albany

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →